• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Research Progress and Challenges of Oligometastasis in Non-small Cell Lung Cancer].[非小细胞肺癌寡转移的研究进展与挑战]
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):467-471. doi: 10.3779/j.issn.1009-3419.2025.102.22.
2
Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.非小细胞肺癌是否存在寡转移状态？文献系统综述。
Lung Cancer. 2013 Nov;82(2):197-203. doi: 10.1016/j.lungcan.2013.07.026. Epub 2013 Aug 20.
3
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
4
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益：系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
5
Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer.日本转移性非小细胞肺癌患者的系统治疗模式及对指南的依从性
Future Oncol. 2025 Apr;21(9):1101-1111. doi: 10.1080/14796694.2025.2470611. Epub 2025 Feb 28.
6
Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States.美国不可切除的 III 期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者接受放化疗的经济负担及医疗服务提供者转诊模式
Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03239-y.
7
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.晚期 NSCLC 中 PD-L1 的表达：系统文献回顾对风险分层和治疗选择的启示。
Lung Cancer. 2017 Oct;112:200-215. doi: 10.1016/j.lungcan.2017.08.005. Epub 2017 Aug 10.
8
Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.非小细胞肺癌寡进展局部消融治疗的频率及预后影响
Thorac Cancer. 2025 Jul;16(13):e70119. doi: 10.1111/1759-7714.70119.
9
Impacts of co-mutations in oligometastatic and oligoprogressive non-small cell lung cancer with mutations-a narrative review of the current literature.寡转移和寡进展性非小细胞肺癌共突变与突变的影响——当前文献的叙述性综述
Transl Lung Cancer Res. 2025 May 30;14(5):1848-1861. doi: 10.21037/tlcr-2024-1121. Epub 2025 May 28.
10
Non-small cell lung cancer (NSCLC): characteristics, risk factors, molecular profile patterns, and treatment - a retrospective cohort study from Palestine.非小细胞肺癌（NSCLC）：特征、危险因素、分子图谱模式及治疗——来自巴勒斯坦的一项回顾性队列研究
J Egypt Natl Canc Inst. 2025 Jul 14;37(1):40. doi: 10.1186/s43046-025-00298-8.

本文引用的文献

1
Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review.寡转移和寡进展性非小细胞肺癌的巩固性放疗：一项系统评价
Crit Rev Oncol Hematol. 2025 Jun;210:104676. doi: 10.1016/j.critrevonc.2025.104676. Epub 2025 Mar 8.
2
Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?循环肿瘤DNA动力学：肺癌放疗个体化的未来工具？
J Liq Biopsy. 2024 Jun 21;6:100160. doi: 10.1016/j.jlb.2024.100160. eCollection 2024 Dec.
3
Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).单臂多中心II期研究：针对伴有寡转移的IV期非小细胞肺癌，采用积极局部巩固治疗联合全身化疗——CURE-OLIGO（TORG1529）
Radiat Oncol. 2025 Jan 4;20(1):2. doi: 10.1186/s13014-024-02577-5.
4
A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation.通过系统文献分析和荟萃分析验证，提出一种新的非小细胞肺癌寡转移简化分类建议，以便于应用。
Eur J Cancer. 2024 Nov;212:115043. doi: 10.1016/j.ejca.2024.115043. Epub 2024 Sep 27.
5
The Proposed Ninth Edition TNM Classification of Lung Cancer.肺癌第九版 TNM 分期系统。
Chest. 2024 Oct;166(4):882-895. doi: 10.1016/j.chest.2024.05.026. Epub 2024 Jun 15.
6
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.标准治疗系统疗法联合或不联合立体定向体部放疗治疗寡进展性乳腺癌或非小细胞肺癌患者（放疗阻断寡进展[CURB]研究）：一项开放标签、随机、对照、2 期研究。
Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14.
7
Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.放疗前ctDNA液体活检用于寡转移非小细胞肺癌的风险分层
NPJ Precis Oncol. 2023 Oct 2;7(1):100. doi: 10.1038/s41698-023-00440-6.
8
The global burden of lung cancer: current status and future trends.全球肺癌负担：现状与未来趋势。
Nat Rev Clin Oncol. 2023 Sep;20(9):624-639. doi: 10.1038/s41571-023-00798-3. Epub 2023 Jul 21.
9
Ultra-high dose-rate proton FLASH improves tumor control.超高剂量率质子 FLASH 可提高肿瘤控制率。
Radiother Oncol. 2023 Sep;186:109741. doi: 10.1016/j.radonc.2023.109741. Epub 2023 Jun 12.
10
[Current Treatment Status and Prospect of Surgery and Thermal Ablation for 
Pulmonary Oligometastases in Non-small Cell Lung Cancer].[非小细胞肺癌肺寡转移瘤的外科手术与热消融治疗现状及展望]
Zhongguo Fei Ai Za Zhi. 2023 Mar 20;26(3):238-244. doi: 10.3779/j.issn.1009-3419.2023.106.06.

[非小细胞肺癌寡转移的研究进展与挑战]

[Research Progress and Challenges of Oligometastasis in Non-small Cell Lung Cancer].

作者信息

Li Songzhen, Shao Tianhang, Yao Shuyang

机构信息

The First Clinical Medical College, Capital Medical University, Beijing 100053, China.

Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):467-471. doi: 10.3779/j.issn.1009-3419.2025.102.22.

DOI:10.3779/j.issn.1009-3419.2025.102.22
PMID:40640097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12257161/
Abstract

Oligometastasis represents a transitional state between early localized disease and widespread metastasis, characterized by limited tumor burden and distinct tumor biological behavior. Due to the relatively restricted number of metastatic lesions and involved organs, aggressive systemic therapy combined with local consolidative therapy offers potential for cure. With rapid advancements in molecular targeted therapies and immunotherapy, comprehensive management of oligometastatic non-small cell lung cancer (NSCLC) has gained increasing attention. This review summarizes the definition of NSCLC oligometastasis, recent therapeutic progress, and existing challenges, aiming to provide insights for clinical diagnosis and treatment strategies.
.

摘要

寡转移代表了早期局限性疾病和广泛转移之间的一种过渡状态，其特征是肿瘤负荷有限且具有独特的肿瘤生物学行为。由于转移病灶和受累器官的数量相对有限，积极的全身治疗联合局部巩固治疗提供了治愈的可能性。随着分子靶向治疗和免疫治疗的迅速发展，寡转移性非小细胞肺癌（NSCLC）的综合管理越来越受到关注。本综述总结了NSCLC寡转移的定义、近期治疗进展和现存挑战，旨在为临床诊断和治疗策略提供见解。